Molecular Residual Disease Detection Market Insight, Size, Share, Growth, Up-To-Date Key Trends, Regional Outlook, and Forecast - 2030
Price : US$ 3,000 | Date : Jul 2023 |
Category : Healthcare and Pharmaceuticals | Pages : 200 |
The Chronic Obstructive Pulmonary Disease (COPD) Market is set to witness immense growth during the forecast period 2022-2028. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, manufacturers/players/vendors analysis, segments & sub-segments, and forecast. The report also focuses on market drivers, challenges (current and future), revenue growth, future roadmap, standardization, deployment models, and forecast analysis.
Overview:
Chronic obstructive pulmonary disease (COPD) is a progressive condition characterized by limited airflow to the lungs. Over 15 million people in the United States suffer from COPD, and many more don't know they have the condition. Women make up more than half of the population, and it is the fourth-leading cause of death and disability in the world. However, while the exact cause is unknown, smoking is a major contributor. Although there is no cure for chronic obstructive pulmonary disease (COPD), a variety of treatments and lifestyle changes can slow its progression and improve your quality of life. Stopping smoking, for example, is the best way to prevent the disease from progressing. Other treatments may include corticosteroids and bronchodilators, which reduce inflammation in the airways. There are also combination inhalers that combine these drugs. Antibiotics, if needed, can also be used to treat bacterial infections.
The global chronic obstructive pulmonary disease (COPD) market focuses on six regions, such as North America, Asia Pacific, South America, Europe, the Middle East, and Africa.
Drivers:
The increasing incidence of chronic obstructive pulmonary disease (COPD) in the world is expected to fuel the growth of the global chronic obstructive pulmonary disease (COPD) market over the forecast period. For instance, according to The Lancet, around 391.9 million individuals in the world, aged 30-79 years of age suffer from COPD. Chronic obstructive pulmonary disease (COPD) can affect any part of the lungs, but the most common symptoms are cough, wheezing, and mucus production. If left untreated, COPD can lead to more serious complications, such as heart problems and respiratory infections. If it is left untreated, COPD can worsen and even lead to death. Chronic bronchitis is another common symptom of COPD. The severity of these symptoms may depend on the individual's lifestyle and the severity of the disease. Moreover, new treatment developments by key players are estimated to enhance the growth of the global chronic obstructive pulmonary disease (COPD) market.
Restraints:
The high cost of treating chronic obstructive pulmonary disease is expected to hinder the growth of the global chronic obstructive pulmonary disease (COPD) market.
Regional Insights:
In regions, North America is expected to dominate the growth of the global chronic obstructive pulmonary disease (COPD) market, owing to the increasing incidence of the disease in the region. For instance, according to the United States Centers for Disease Control and Prevention, COPD affects over 15 million Americans. Moreover, the Asia Pacific is estimated to witness significant growth in the global chronic obstructive pulmonary disease (COPD) market owing to the increasing prevalence of key players in the region, along with the expansion of healthcare facilities.
Competitive Section:
Key players operating in the global chronic obstructive pulmonary disease (COPD) market include Verona Pharmaceuticals, Theravance Biopharma, Teva Pharmaceutical Industries Ltd., Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd.), Sanofi, Orion Corporation, Novartis AG, Mylan N.V., Kyowa Hakko Kirin, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., CHIESI Farmaceutici S.p.A., Boehringer Ingelheim International GmbH, AstraZeneca, and Almirall.
In October 2021, the United States gave approval to Mylan Pharmaceuticals for the investigational new drug application (ANDA) called Breyna, which is the first accepted generic version of Symbicort by AstraZeneca.
In January 2019, CHIESI Farmaceutici S.p.A. and TiumBio entered into an agreement.
Chronic Obstructive Pulmonary Disease (COPD) Market Dynamics:
This market study estimates the market size in terms of both value (million USD) and volume (K Units). The Chronic Obstructive Pulmonary Disease (COPD) Market report analyses market trends based on historical data and the latest developments. It provides both qualitative and quantitative data on the elements that will shape the market's growth from 2022 to 2028. The market capacity and consumption potential of major companies are discussed in this research report. Furthermore, it concentrates on prominent regions (Latin America, Europe, Asia Pacific, Africa, and the Middle East). Also, the report evaluates COVID-19's impact on the Chronic Obstructive Pulmonary Disease (COPD) Market.
Companies profiled in the Chronic Obstructive Pulmonary Disease (COPD) Market report include:
The report covers extensive competitive intelligence which includes the following data points:
⇨ Business Overview
⇨ Business Model
⇨ Financial Data
⇨ Financial – Existing
⇨ Financial – Funding
⇨ Product/Service Segment Analysis and specification
⇨ Recent Development and Company Strategy Analysis
⇨ SWOT Analysis
Segmentation by Type:
The type segment contributed the largest share to the Chronic Obstructive Pulmonary Disease (COPD) Market in 2021; this segment is projected to grow at the highest CAGR from 2022 to 2028.
Segmentation by Application:
An end-use industry is projected to grow at the highest CAGR during the forecast period, due to rapid development in emerging economies North America, APAC, MEA, Europe, and ROW.
Key Benefits for Stakeholders:
Reasons to Purchase Chronic Obstructive Pulmonary Disease (COPD) Market Report:
Research Methodology:
To estimate and validate the size of the Chronic Obstructive Pulmonary Disease (COPD) Market and many other dependent submarkets in the overall market, both top-down and bottom-up methodologies are utilized. Key players in the market have been identified through secondary research and their market shares have been determined through primary and secondary research. Secondary sources and verified primary sources were used to determine all percentage share splits and breakdowns.
* Browse 15 Market Data Tables and 32 Figures on “Chronic Obstructive Pulmonary Disease (COPD) Market Market” – Forecast to 2028.
Price : US$ 3,000 | Date : Jul 2023 |
Category : Healthcare and Pharmaceuticals | Pages : 200 |
Price : US$ 3,000 | Date : May 2023 |
Category : Healthcare and Pharmaceuticals | Pages : 154 |
Price : US$ 3,000 | Date : May 2023 |
Category : Healthcare and Pharmaceuticals | Pages : 161 |
Price : US$ 3,000 | Date : May 2023 |
Category : Healthcare and Pharmaceuticals | Pages : 165 |
Price : US$ 3,000 | Date : May 2023 |
Category : Healthcare and Pharmaceuticals | Pages : 164 |
In search of customized market research solution? We are here to help you. Contact us.